Literature DB >> 9828210

KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma.

X Z Guo1, H Friess, F F Di Mola, J M Heinicke, M Abou-Shady, H U Graber, H U Baer, A Zimmermann, M Korc, M W Büchler.   

Abstract

Down-regulation of KAI1 expression has been shown to be associated with formation of metastases or disease progression in prostate and pancreatic cancer. In the present study we analyzed the expression pattern of KAI1 in metastatic and nonmetastatic hepatocellular carcinomas (HCCs) in comparison with normal livers to evaluate whether alteration of KAI1 also facilitates the metastatic ability in this malignancy. Thirty-nine primary HCCs and 10 normal liver tissue samples were studied for KAI1 messenger RNA (mRNA) expression with use of Northern blot analysis and in situ hybridization. By Northern blot analysis, moderate to strong KAI1 mRNA expression was present in normal liver samples. In contrast, KAI1 mRNA expression in tissue samples of primary HCCs was markedly decreased compared with normal controls. The normal/tumor ratio of KAI1 mRNA expression was 2.6:1 (P <.01). Primary HCCs that gave rise to metastasis showed significantly lower KAI1 mRNA levels than nonmetastasized HCCs (P <. 05). As seen by in situ hybridization, moderate to strong cytoplasmic KAI1 mRNA staining was present in almost all normal hepatocytes. Bile ducts, blood vessels, and connective tissue showed no or only faint KAI1 mRNA expression in the normal liver samples. In nonmetastatic HCCs, the cancer cells exhibited in situ hybridization signals that were similar to the normal controls. In contrast, most of the primary HCC cells in samples with metastases showed only faint or moderate KAI1 mRNA expression predominantly in the perinuclear regions. When KAI1 mRNA expression of primary hepatocellular cancer cells was compared with metastasized cancer cells in lymph nodes, with intrahepatic satellite metastasis, or with peritoneal metastasis in the same patients, significantly lower (P <.01) KAI1 mRNA levels were present in the metastasized HCC cells. Reduced KAI1 mRNA in HCC cells seems to influence their metastatic ability and thereby enhances the malignant potential of HCC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828210     DOI: 10.1002/hep.510280606

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

1.  KAI1 gene is differently expressed in papillary and pancreatic cancer: influence on metastasis.

Authors:  Xiao-Zhong Guo; Helmut Friess; Xiao-Dong Shao; Min-Pei Liu; Yu-Ting Xia; Jian-Hua Xu; Markus W Buchler
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 2.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas.

Authors:  H Friess; L Wang; Z Zhu; R Gerber; M Schröder; A Fukuda; A Zimmermann; M Korc; M W Büchler
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

4.  KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma.

Authors:  F S Liu; J T Chen; J T Dong; Y T Hsieh; A J Lin; E S Ho; M J Hung; C H Lu
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

5.  MTSS1 is an independent prognostic biomarker for survival in intrahepatic cholangiocarcinoma patients.

Authors:  Wei Shi; Gulimire Hasimu; Yan Wang; Ning Li; Mingquan Chen; Hao Zhang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

6.  Loss of the eukaryotic initiation factor 3f in pancreatic cancer.

Authors:  Adriana Doldan; Anupama Chandramouli; Reneé Shanas; Achyut Bhattacharyya; John T Cunningham; Mark A Nelson; Jiaqi Shi
Journal:  Mol Carcinog       Date:  2008-03       Impact factor: 4.784

Review 7.  Metastasis suppressors: functional pathways.

Authors:  Imran Khan; Patricia S Steeg
Journal:  Lab Invest       Date:  2017-10-02       Impact factor: 5.662

8.  FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model.

Authors:  Ulrich Deuschle; Julia Schüler; Andreas Schulz; Thomas Schlüter; Olaf Kinzel; Ulrich Abel; Claus Kremoser
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

Review 9.  Nm23/NDP kinases in hepatocellular carcinoma.

Authors:  Mathieu Boissan; Marie-Lise Lacombe
Journal:  J Bioenerg Biomembr       Date:  2006-08       Impact factor: 3.853

10.  The role of SRC family kinases in prostate cancer.

Authors:  Oleg Tatarov; Joanne Edwards
Journal:  Transl Oncogenomics       Date:  2007-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.